Battelle https://www.battelle.org, and Spark Biomedical, Inc., https://www.sparkbiomedical.com a developer of wearable neurostimulation solutions, are going to do a pilot clinical study to advance remote detection and treatment of OUDs.
The study’s primary objective is to collect physiological data via biosensors from patients experiencing opioid withdrawal symptoms, cravings, and addiction-related psychological stressors using the Battelle NeuroHub System. The team will develop an Artificial Intelligence (AI) algorithm from the data.
Spark and Battelle plan to use the resulting opioid withdrawal algorithm to:
- Develop a new more objective physiological assessment tool for opioid withdrawal measurement
- Develop AI and machine learning algorithms to better understand mental health states
- Move towards the development of a closed loop neurostimulation solution for opioid withdrawal
Healthcare trends continue to shift towards wearable technology, self-assessment, and telemedicine to provide patients consistent, reliable, and in the moment treatment options. The opioid epidemic continues to grow and treatment options remain scarce in high impacted rural populations.
By inserting AI machine learning and wearable solutions into the opioid use disorder treatment lifecycle may introduce and provide much needed accuracy, availability, and portability for both providers and patients.
The jointly run pilot clinical study is estimated to begin in the summer of 2022 and run through the year. Once completed, the teams will start work to leverage the data and the companies’ respective technology solutions with the goal to create a new holistic closed-loop opioid withdrawal assessment and treatment solution.